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1. INTRODUCTION {#jcmm13799-sec-0001}
===============

miRNAs are a class of small noncoding RNAs which are associated with a variety of complex biological processes.[1](#jcmm13799-bib-0001){ref-type="ref"} Increasing studies have shown that miRNAs play a vital role in various biological processes which are essential for human life, including cell proliferation, differentiation, ageing and apoptosis.[2](#jcmm13799-bib-0002){ref-type="ref"}, [3](#jcmm13799-bib-0003){ref-type="ref"}, [4](#jcmm13799-bib-0004){ref-type="ref"}, [5](#jcmm13799-bib-0005){ref-type="ref"} In the meanwhile, evidence have demonstrated that miRNAs are related with a number of common neoplasms, such as breast neoplasms,[6](#jcmm13799-bib-0006){ref-type="ref"} lung neoplasms[7](#jcmm13799-bib-0007){ref-type="ref"} and prostate neoplasms.[8](#jcmm13799-bib-0008){ref-type="ref"} Therefore, the research on prediction of potential associations between miRNAs and diseases provides new opportunities to study the molecular mechanisms of diseases. During the past few years, a large number of associations have been confirmed by traditional experiments.[9](#jcmm13799-bib-0009){ref-type="ref"}, [10](#jcmm13799-bib-0010){ref-type="ref"} Although reliable, experimental methods are generally time‐consuming and expensive. As a result, effective computational methods are urgently needed to uncover potential associations between miRNAs and diseases.

Recently, a great number of computational methods have been proposed to identify miRNA‐disease associations. Under the assumption that miRNAs with similar functions are tend to be related with phenotypically similar diseases and vice versa,[11](#jcmm13799-bib-0011){ref-type="ref"} Jiang et al[12](#jcmm13799-bib-0012){ref-type="ref"} proposed the first computational model to predict miRNA‐disease associations by integrating the disease phenotype similarity network, miRNA functional similarity network and known phenome‐microRNAome network to build a heterogeneous network. Based on weighted K most similar neighbours, Xuan et al[13](#jcmm13799-bib-0013){ref-type="ref"} presented HDMP to predict the associations between miRNAs and diseases. The miRNA functional similarity was calculated by disease terms and the disease phenotype similarity. Considering the fact that the accuracy of local network similarity measures is lower than that of global network similarity measures,[14](#jcmm13799-bib-0014){ref-type="ref"}, [15](#jcmm13799-bib-0015){ref-type="ref"}, [16](#jcmm13799-bib-0016){ref-type="ref"}, [17](#jcmm13799-bib-0017){ref-type="ref"} Chen et al[18](#jcmm13799-bib-0018){ref-type="ref"} presented the first global method named RWRMDA by adopting random walk on the miRNA functional similarity network. However, RWRMDA cannot be applied to diseases without any known related miRNAs. Since then, many classical methods based on random walk were proposed to predict the latent miRNA‐disease associations. The main difference of these methods lies in the constructed networks on which the random walk was applied. Shi et al[19](#jcmm13799-bib-0019){ref-type="ref"} adopted random walk model to identify miRNA‐disease associations by integrating miRNA‐target relationship, disease‐genes in protein‐protein network. Later, Liu et al[20](#jcmm13799-bib-0020){ref-type="ref"} first calculated miRNA similarity based on the miRNA‐target and miRNA‐IncRNA associations, and they then constructed a heterogeneous network by integrating the semantic and functional similarities of disease, miRNA similarity and known miRNA‐disease associations. Similarly, Luo et al[21](#jcmm13799-bib-0021){ref-type="ref"} also constructed a heterogeneous network by integrating miRNA similarity, disease semantic similarity and known miRNA‐disease associations. However, they used an imbalanced birandom walk to identify miRNA‐related diseases. Chen et al[22](#jcmm13799-bib-0022){ref-type="ref"} proposed WBSMDA which integrates the Gaussian Interaction profile into the construction of similarity matrices. Specifically, WBSMDA calculated a within‐score and a between score, and combined them together to obtain a final score for miRNA‐disease associations prediction. Using the same data, they further proposed another method named HGIMDA.[23](#jcmm13799-bib-0023){ref-type="ref"} They first constructed a heterogeneous graph, and then implemented an iterative process on the graph to discover the relationships between miRNAs and diseases. HGIMDA was proved to be fast and effective compared to the aforementioned methods.

Recently, many path‐based methods were proposed to predict miRNA‐disease associations. Based on the lengths of different walks, the KATZ model was originally used in the social networks. Zou et al[24](#jcmm13799-bib-0024){ref-type="ref"} and Qu et al[25](#jcmm13799-bib-0025){ref-type="ref"} skillfully applied KATZ to predict the potential miRNA‐disease associations and achieved reliable results. You et al[26](#jcmm13799-bib-0026){ref-type="ref"} presented an effective method based on paths of different lengths. They constructed a heterogeneous network and applied depth‐first search algorithm to uncover the potential associations between miRNAs and disease. By taking the network topological structure into account, PBMDA achieved remarkable performance. Nevertheless, the searching process for paths of a certain length could be extremely time‐consuming in large networks. Recently, Chen et al[27](#jcmm13799-bib-0027){ref-type="ref"} proposed a method GIMDA to predict miRNA‐disease associations, in which the related score of a miRNA to a disease was calculated by measuring the graphlet interactions between two miRNAs or two diseases. They also[28](#jcmm13799-bib-0028){ref-type="ref"} proposed another model called NDAMDA based on network distance to predict miRNA‐disease associations. In this study, they considered not only the direct distance between two miRNAs (diseases), but also the average distance to other miRNAs (diseases).

Several machine learning‐based models were also developed to predict potential miRNA‐disease associations. Jiang et al[29](#jcmm13799-bib-0029){ref-type="ref"} trained a support vector machine classifier to distinguish positive miRNA‐disease associations from negative ones. Chen et al[30](#jcmm13799-bib-0030){ref-type="ref"} constructed a continuous classification function based on regularized least squares to reflect the probability of each miRNA related to a given disease. Subsequently, Luo et al[31](#jcmm13799-bib-0031){ref-type="ref"} presented an effective method KRLSM, which integrated different omics data and applied regularized least squares to discover the relationship between miRNAs and diseases. Recently, Chen et al[32](#jcmm13799-bib-0032){ref-type="ref"} proposed DRMDA using stacked auto‐encoder, greedy layer‐wise unsupervised pretraining algorithm and SVM to identify miRNA related with diseases. They also proposed another two machine learning‐based methods MKRMDA and EGBMMDA.[33](#jcmm13799-bib-0033){ref-type="ref"}, [34](#jcmm13799-bib-0034){ref-type="ref"} Specifically, MKRMDA could automatically optimize the combination of multiple kernels for disease and miRNA based on Kronecker regularized least squares. In EGBMMDA, a model of extreme gradient boosting machine was applied to identify miRNA‐disease associations. EGBMMDA achieved a high prediction accuracy in the framework of cross‐validation.

Although existing computational methods have made outstanding contributions in this filed, there is still room for further improvement. In this study, we present a reliable method based on Sparse Neighborhood to predict the MiRNA‐Disease Associations (SNMDA). SNMDA mainly consists of three steps. First, we use the sparse reconstruction to obtain the reconstructed similarity matrices both for miRNA and disease by considering the neighbourhood information. Second, we integrated similarity information to construct a similarity network for miRNAs and diseases, respectively. Third, we predicted the potential miRNA‐disease associations through label propagation[35](#jcmm13799-bib-0035){ref-type="ref"}, [36](#jcmm13799-bib-0036){ref-type="ref"}, [37](#jcmm13799-bib-0037){ref-type="ref"} on the miRNA similarity network as well as disease similarity network to obtain the final prediction result. To demonstrate the effectiveness of our method, we applied global LOOCV, local LOOCV and 5‐fold cross‐validation to evaluate the performance of our method, respectively. The corresponding AUCs are 0.936, 0.882 and 0.934, which in all cases outperform the four state‐of‐the‐art methods (HGIMDA,[23](#jcmm13799-bib-0023){ref-type="ref"} PBMDA,[26](#jcmm13799-bib-0026){ref-type="ref"} EGBMMDA [34](#jcmm13799-bib-0034){ref-type="ref"} and MKRMDA[33](#jcmm13799-bib-0033){ref-type="ref"}). Moreover, three types of case studies on five common neoplasms further validated the effectiveness of our method. Taken together, these results demonstrated that our method can effectively discover the underlying miRNA‐disease associations.

2. MATERIALS AND METHODS {#jcmm13799-sec-0002}
========================

2.1. Known miRNA‐disease associations {#jcmm13799-sec-0003}
-------------------------------------

The human miRNA‐disease associations (HMDD)[38](#jcmm13799-bib-0038){ref-type="ref"} is a database containing experimentally verified miRNA‐disease associations. The known associations used in this paper were downloaded from the latest version HMDD v2.0 (<http://www.cuilab.cn/hmdd>). After filtering, 5430 associations between 383 diseases and 495 miRNAs were obtained. For convenience, we define an adjacency matrix *A* to describe the known miRNA‐disease associations. For a given disease *i* and a miRNA *j*,*A*(*i, j*) *=* 1 if *i* is related to *j*, and *A*(*i, j*) *=* 0 otherwise. Our goal is to confirm the uncertain associations between miRNAs and diseases.

2.2. miRNA functional similarity {#jcmm13799-sec-0004}
--------------------------------

According to previous study,[39](#jcmm13799-bib-0039){ref-type="ref"} the miRNA functional similarity was calculated based on the assumption that functionally similar miRNAs tend to be associated with similar diseases. Benefitting from their results, here we directly downloaded the miRNA functional similarity from <http://www.cuilab.cn/files/images/cuilab/misim.zip>. An adjacency matrix MFS was built to represent the similarity of miRNAs, where MFS(*i, j*) represents the similarity score between miRNA *i* and miRNA *j*. The larger the MFS(*i, j*) is, the closer their associations will be.

2.3. Disease semantic similarity {#jcmm13799-sec-0005}
--------------------------------

Mesh database provides a strict classification system for disease. Each disease can be described as a directed acyclic graph (DAG).[39](#jcmm13799-bib-0039){ref-type="ref"} DAG is made up of points and links. For a given disease *d*, DAG*=* (*d*,*T*(*d*), *E*(*d*)), where *T*(*d*) represents its ancestor nodes and itself, and *E*(*d*) is the set of links of *d*. Disease *t* is one of *T*(*d*), and the contribution to disease *d* can be calculated as follows[25](#jcmm13799-bib-0025){ref-type="ref"}: $$\left\{ \begin{matrix}
{D_{d}\left( d \right) = 1} \\
{D_{d}\left( t \right) = \max\left\{ {0.5 \ast D_{d}\left( t^{\prime} \right)\left| {t^{\prime} \in \text{child\ of}\, t} \right.} \right\}\text{if}\, t \neq d} \\
\end{matrix} \right.$$We define the contribution to itself is 1 while others are 0.5. Therefore, we can use the following formula to calculate the semantic value of *d*. $$\text{DV}\left( d \right) = \sum_{T \in T_{d}}{D_{d}\left( t \right)}$$ Then, we calculate the semantic similarity between disease *a* and disease *b* through the following formula. $$S\left( {a,b} \right) = \frac{\sum_{T \in T_{a} \cap T_{b}}\left( {D_{a}\left( t \right) + D_{b}\left( t \right)} \right)}{\text{DV}\left( a \right) + \text{DV}\left( b \right)}$$ *D* ~*d*~(*t*) represents the contribution of disease *t* to disease *a* while *D* ~*b*~(*t*) represents the contribution of disease *t* to disease *b*. From Equation [(3)](#jcmm13799-disp-0003){ref-type="disp-formula"}, we found that the semantic similarity for *a* and *b* depend on the number of their common diseases. The larger the number is, the greater the similarity will be. By calculating the semantic similarity of each disease pair according to Equation [(3)](#jcmm13799-disp-0003){ref-type="disp-formula"}, we could obtain an adjacency matrix DSS. DSS(*i,j*) represents the semantic similarity between disease *i* and disease *j*.

2.4. SNMDA {#jcmm13799-sec-0006}
----------

As described in the first section, SNMDA could be divided into three steps and the first step was the key to our approach. Specifically, we reconstructed miRNA similarity (RMS) and disease similarity (RDS) by taking the sparse neighbourhood into account. An overall workflow was illustrated in Figure [1](#jcmm13799-fig-0001){ref-type="fig"}. The details of SNMDA are as follows.

![An overall workflow of SNMDA to predict miRNA‐disease associations](JCMM-22-5109-g001){#jcmm13799-fig-0001}

### 2.4.1. Feature representation {#jcmm13799-sec-0007}

In general, the sparse neighbourhood representation is constructed based on feature vectors. Therefore, the miRNAs and diseases are required to be in the form of feature vectors. Here, "interaction profile"[36](#jcmm13799-bib-0036){ref-type="ref"}, [37](#jcmm13799-bib-0037){ref-type="ref"} is adopted to describe the feature vectors according to the known miRNA‐disease associations. An example is given in Figure [2](#jcmm13799-fig-0002){ref-type="fig"}.

![An example of feature representation](JCMM-22-5109-g002){#jcmm13799-fig-0002}

As shown in Figure [2](#jcmm13799-fig-0002){ref-type="fig"}, the miRNA‐disease interaction network consists of 5 miRNAs and 5 diseases, where $\left\{ \left. {M1,M2,M3,M4,M5} \right\} \right.$ and $\left\{ \left. {D1,D2,D3,D4,D5} \right\} \right.$ represent the miRNA set and disease set, respectively. If miRNA *M1* is known to be related with disease *D*1, the value in the corresponding adjacency matrix of the interaction network is 1, and 0 otherwise. Each column represents the feature vector of one miRNA, and each row represents the feature vector of one disease. For example, the feature vector of *M*1 can be represented as (1, 1, 0, 1, 0) and that of *D*1 is represented as (1, 0, 1, 0, 0).

### 2.4.2. Reconstruction of similarity for miRNAs and diseases {#jcmm13799-sec-0008}

Generally, the functional similarity of miRNAs as well as the semantic similarity of diseases is used to predict the relationships between miRNAs and diseases directly. However, they are still far from complete since many of the associations are uncovered yet. To solve this limitation, we first carried out a degree distribution analysis for the constructed miRNA‐disease association network (Figure [3](#jcmm13799-fig-0003){ref-type="fig"}). Obviously, power‐law distributions for both known disease‐associated miRNAs and known miRNA‐associated diseases were observed. In other words, most diseases as well as miRNAs only have very few known associations, which results in a very sparse heterogeneous network constructed by the known miRNA‐disease associations. Therefore, how to take advantage of this sparsity and further improve the prediction accuracy of the associations between miRNAs and diseases is a meaningful task.

![Degree distribution analysis for the constructed miRNA‐disease association network](JCMM-22-5109-g003){#jcmm13799-fig-0003}

In this section, we present a novel method to integrate the sparse information into the existing similarity information by reconstructing the miRNA similarity and disease similarity with sparse representation. Sparse representation has received extensive attention in pattern recognition and machine learning.[40](#jcmm13799-bib-0040){ref-type="ref"}, [41](#jcmm13799-bib-0041){ref-type="ref"}, [42](#jcmm13799-bib-0042){ref-type="ref"} Before calculating the reconstructed similarity, we first briefly introduce the definition of sparse neighbourhood and sparse reconstruction.

#### Sparse neighbourhood {#jcmm13799-sec-0009}

The sparse neighbourhood of the sample *x* ~*i*~ (*i = 1, 2,..., n*) is defined as follows. First, set a parameter *ε* (*ε \>* 0) as the threshold. Then, compare the reconstructed coefficients with parameter *ε*. If reconstruction coefficient *α* ~*j*~ \> *ε*, ($i \neq j$), we say *x* ~*j*~ is one of the sparse neighbourhoods of samples *x* ~*i*~. Otherwise, it does not belong to the sparse neighbourhoods of *x* ~*i*~.[35](#jcmm13799-bib-0035){ref-type="ref"}

#### Sparse reconstruction {#jcmm13799-sec-0010}

Suppose we have an uncertain linear equation *x = D*α (*i = 1, 2,..., n*), where sample *x* is an *n*‐dimensional vector to be reconstructed, and *D* represents an over complete dictionary. α is a coefficient vector whose entries represent the correlation scores of sample *x* with other samples. Our motivation is to calculate the vector α. We can solve this problem by optimizing the following formula: $$\min\limits_{\alpha}{||\alpha||}_{0}\,\text{s.t.}x = D\alpha$$L0‐norm is the number of nonzero elements in the vector. However, it is known as a NP‐hard problem to find the sparsest solution for L0‐norm. As L1‐norm is the closest convex form to L0‐norm,[43](#jcmm13799-bib-0043){ref-type="ref"} a common approach to solve this problem is to replace the L0‐norm with the L1‐norm.[43](#jcmm13799-bib-0043){ref-type="ref"} Consequently, the problem is equal to minimize the following optimizing problem: $$\min\limits_{\alpha}{||\alpha||}_{1}\text{s.t.}x = D\alpha$$L1‐norm represents the sum of the absolute values of each element in a vector. *D* represents a dictionary. We can obtain a relevance score matrix by solving Equation [(6)](#jcmm13799-disp-0006){ref-type="disp-formula"}. Considering that many scores in the matrix are very small, we only selected the sparse neighbourhood for each sample to reconstruct each sample by Equation [(6)](#jcmm13799-disp-0006){ref-type="disp-formula"}. $$\min\limits_{w}{||w||}_{1}\text{s.t.}x = Dw$$Eventually, we obtained a new matrix which is reconstructed by the sparse neighbourhood of each sample.

We have introduced sparse neighbourhood and sparse reconstruction. Next, we will introduce how to compute the reconstructed miRNA similarity and disease similarity. In the previous section, miRNAs and diseases have been represented as feature vectors and were regarded as points which were projected into a feature space, respectively. In our method, we assume that points are linearly arranged in the feature space, and every point can be reconstructed by other points.

### 2.4.3. Integration of similarity information {#jcmm13799-sec-0011}

After RDS and RMS were obtained, we integrated them into existing similarity matrices. The final miRNA similarity matrix (FMS) and final disease similarity matrix (FDS) were then used to predict the potential miRNA‐disease associations. Specifically, given a miRNA *x* and a miRNA *y*, if MFS(*x, y*)=0*,* then FMS(*x, y*) = RDS(*x, y*); otherwise, FMS(*x, y*) = (RMS(*x, y*) + MFS(*x, y*))/2. The FDS was calculated in the same way. The formulas are as follows: $$\text{FMS}\left( {x,y} \right) = \left\{ \begin{matrix}
{\text{RMS}\left( {x,y} \right),\,\text{if}\,\text{MFS}\left( {x,y} \right) = 0} \\
{\frac{\text{RMS}\left( {x,y} \right) + \text{MFS}\left( {x,y} \right)}{2},\text{otherwise}} \\
\end{matrix} \right.$$ $$\text{FDS}\left( {x,y} \right) = \left\{ \begin{matrix}
{\text{RDS}\left( {x,y} \right),\,\mspace{6mu}\text{if}\,\text{DSS}\left( {x,y} \right) = 0} \\
{\frac{\text{RDS}\left( {x,y} \right) + \text{DSS}\left( {x,y} \right)}{2},\text{otherwise}} \\
\end{matrix} \right.$$According to Equation [(7)](#jcmm13799-disp-0007){ref-type="disp-formula"}, we constructed a miRNA similarity network where nodes are miRNAs and edges represent their similarity. A disease similarity network was constructed in the same way according to Equation [(8)](#jcmm13799-disp-0008){ref-type="disp-formula"}.

### 2.4.4. Label propagation {#jcmm13799-sec-0012}

Label propagation was applied on both miRNA and disease networks to obtain the prediction results. The labels were initiated with the known miRNA‐disease associations and were updated through label propagation. First, labels were propagated in the miRNA similarity network. In the process of label propagation, each point retains the information from its neighbours and receives its initial label information. Parameter *α* (0 \< *α* \< 1) is used to control the rate of retaining the information from its neighbours while 1‐*α* represents the probability of receiving its initial label information. Therefore, the iteration equation can be written as follows: $$F\left( {t + 1} \right) = \alpha{} \ast \text{FMS}{} \ast F\left( t \right) + \left( {1 - \alpha} \right){} \ast Y$$According to previous studies,[44](#jcmm13799-bib-0044){ref-type="ref"}, [45](#jcmm13799-bib-0045){ref-type="ref"} Equation [(9)](#jcmm13799-disp-0009){ref-type="disp-formula"} is guaranteed to converge if FMS is properly normalized by Equation [(10)](#jcmm13799-disp-0010){ref-type="disp-formula"}: $$\text{MS} = D^{- 1/2}{} \ast \text{FMS}{} \ast D^{1/2}$$where *D* is a diagonal matrix with its (*i*,*i*)‐th element equal to the sum of *i*‐th row in FMS. We used the same way to deal with FDS. Therefore, Equation [(9)](#jcmm13799-disp-0009){ref-type="disp-formula"} was rewritten in the following form: $$F_{M}\left( {t + 1} \right) = \alpha{} \ast \text{MS}{} \ast F_{M}\left( t \right) + \left( {1 - \alpha} \right){} \ast Y$$Equation [(11)](#jcmm13799-disp-0011){ref-type="disp-formula"} was then used to update the label information for each miRNA until convergence. *F* ~*M*~(*t +* 1) represents the label matrix in the (*t +* 1)‐*th* iteration. *Y* is the initial label matrix and *F*(0) *= Y*. When the iterative formula converges, *F* ~*M*~(*t +* 1) was treated as the final correlation score matrix. Similarly, when labels are propagated in the disease similarity network, the iteration equation on the disease similarity network could be written as follows: $$F_{D}\left( {t + 1} \right) = \alpha{} \ast \text{DS}{} \ast F_{D}\left( t \right) + \left( {1 - \alpha} \right){} \ast Y^{\prime}$$

Taken together, the final correlation score matrix is calculated by: $$F = \beta F_{M} + \left( {1 - \beta} \right){F_{D}}^{\prime}$$here, *β* was set to 0.5.

The complete process of SNMDA was outlined in Algorithm [1](#jcmm13799-sec-0020){ref-type="sec"}.

### 2.4.5. Implementation details {#jcmm13799-sec-0013}

SNMDA was implemented in MATLAB under the MATLAB R2016b programming environment. Specifically, the L1‐norm optimization problem was solved by the l1_ls MATLAB software package. All the experiments were performed on a desktop with an i7‐6700 3.40 GHz CPU and 16G RAM. The source code and data sets used in this work could be freely downloaded at <https://github.com/misitequ/SNMDA>.

3. RESULTS {#jcmm13799-sec-0014}
==========

3.1. Evaluation {#jcmm13799-sec-0015}
---------------

We applied leave‐one‐out cross‐validation (LOOCV), and 5‐fold cross‐validation to test the prediction ability of our method. LOOCV can be conducted in two different ways: global and local LOOCV. In the framework of global LOOCV, each known miRNA‐disease association was left out in turn as the test sample and the other known associations were regarded as training samples.[46](#jcmm13799-bib-0046){ref-type="ref"} After each prediction, the ranking of the test sample was compared with all the unconfirmed miRNA‐disease associations. If the ranking of the test sample was higher than a given threshold, it was marked as a successful prediction. In comparison, in the framework of local LOOCV, each known miRNA associated with a given disease was left out in turn as the test sample and the ranking of that test sample was only compared with the unconfirmed associations of this specific disease.[26](#jcmm13799-bib-0026){ref-type="ref"} Both frameworks were repeated 5430 times. In addition, 5‐fold cross‐validation was also implemented to evaluate our method. In 5‐fold cross‐validation, all the known miRNA‐disease associations were divided into five disjoint subsets. Each subset was taken as test samples in turn while the rests were considered as training samples. To avoid the bias caused by sample divisions, we repeated 5‐fold cross‐validation 20 times and the final result is given by averaging the results from the 20 repetitions. Furthermore, the receiver operating characteristic (ROC) curves were plotted by calculating false‐positive rate (FPR) and true‐positive rate (TPR) at varying thresholds. The area under curve (AUC) was then calculated for comprehensive performance evaluations.

As a result, SNMDA achieved reliable AUCs of 0.936, 0.882 and 0.934 for global LOOCV, local LOOCV and 5‐fold cross‐validation, respectively (Figure [4](#jcmm13799-fig-0004){ref-type="fig"}). To further prove the performance of SNMDA, we compared our method with four state‐of‐the‐art methods (HGIMDA,[23](#jcmm13799-bib-0023){ref-type="ref"} PBMDA,[26](#jcmm13799-bib-0026){ref-type="ref"} EBMMDA[34](#jcmm13799-bib-0034){ref-type="ref"} and MKRMDA[33](#jcmm13799-bib-0033){ref-type="ref"}). As shown in Figure [4](#jcmm13799-fig-0004){ref-type="fig"}. In global LOOCV, HGIMDA, EBMMDA, PBMDA and MKRMDA achieved AUCs of 0.875, 0.922, 0.912 and 0.904, respectively, and the AUC obtained by SNMDA was higher than the other four methods by 0.061, 0.014, 0.024 and 0.032. In the framework of local LOOCV, the AUCs of HGIMDA, EBMMDA, PBMDA and MKRMDA were 0.823, 0.853, 0.807 and 0.827, all of which were lower than that of SNMDA. In five‐fold cross‐validation, the corresponding AUCs of the four methods were 0.867, 0.916, 0.904 and 0.88, respectively, where the performance of SNMDA consistently outperformed the other four alternatives. In conclusion, the cross‐validation results verified the superior ability of SNMDA in prediction the underlying associations between miRNAs and diseases.

![The results between SNMDA and the other methods (HGIMDA,EGBMMDA,PBMDA and MKRMDA) in terms of global LOOCV, local LOOCV and 5‐fold cross‐validation](JCMM-22-5109-g004){#jcmm13799-fig-0004}

3.2. Case study {#jcmm13799-sec-0016}
---------------

In this section, we carried out three types of case studies to further validate the effectiveness of SNMDA. For the first type of case studies, we applied SNMDA to predict novel miRNA‐disease associations for three selected diseases based on the known associations from HMDD v2.0, that is breast neoplasms, lung neoplasms and prostate neoplasms. The prediction results for each disease were verified by two databases PhenomiR[47](#jcmm13799-bib-0047){ref-type="ref"} and dbDEMC,[48](#jcmm13799-bib-0048){ref-type="ref"} both of which provide differentially expressed miRNAs for certain diseases.

Breast neoplasms is a common disease in women and also a serious threat to the health of women.[49](#jcmm13799-bib-0049){ref-type="ref"}, [50](#jcmm13799-bib-0050){ref-type="ref"} In the early years, the mortality of breast neoplasms is just inferior to lung neoplasms. With the development of comprehensive treatment of breast neoplasms, the mortality rate has been significantly reduced. Researchers have found that many miRNAs are associated with breast neoplasms by clinical experiments, such as mir‐155 and mir‐21.[6](#jcmm13799-bib-0006){ref-type="ref"} We used our method to predict the candidate miRNAs for breast neoplasms, and we listed the top 50 predicted candidate miRNAs (Table [1](#jcmm13799-tbl-0001){ref-type="table"}). As a result, 49 of the top 50 candidate miRNAs were successfully verified. For example, hsa‐mir‐150 (1st in Table [1](#jcmm13799-tbl-0001){ref-type="table"}) and hsa‐mir‐130a are closely related to breast neoplasms. Hsa‐mir‐150 can promote human breast neoplasms growth[51](#jcmm13799-bib-0051){ref-type="ref"} while hsa‐mir‐130a (3rd in Table [1](#jcmm13799-tbl-0001){ref-type="table"}) could suppress breast neoplasms cell migration and invasion.[52](#jcmm13799-bib-0052){ref-type="ref"} The only unconfirmed miRNA was hsa‐mir‐507. As a matter of fact, Jia et al[53](#jcmm13799-bib-0053){ref-type="ref"} have reported that hsa‐mir‐507 inhibits the migration and invasion of human breast neoplasms cells. Our prediction results provided new evidence for its role in the pathogenesis of breast neoplasms.

###### 

The top 50 predicted miRNAs associated with breast neoplasms

  miRNA (1‐25)   Evidence           miRNA (26‐50)   Evidence
  -------------- ------------------ --------------- ------------------
  hsa‐mir‐150    dbDEMC; PhenomiR   hsa‐mir‐181d    dbDEMC; PhenomiR
  hsa‐mir‐106a   dbDEMC; PhenomiR   hsa‐mir‐552     dbDEMC
  hsa‐mir‐130a   dbDEMC; PhenomiR   hsa‐mir‐494     dbDEMC; PhenomiR
  hsa‐mir‐192    dbDEMC; PhenomiR   hsa‐mir‐330     dbDEMC; PhenomiR
  hsa‐mir‐15b    dbDEMC; PhenomiR   hsa‐mir‐198     dbDEMC; PhenomiR
  hsa‐mir‐142    PhenomiR           hsa‐mir‐376a    dbDEMC; PhenomiR
  hsa‐mir‐30e    PhenomiR           hsa‐mir‐211     dbDEMC; PhenomiR
  hsa‐mir‐98     dbDEMC; PhenomiR   hsa‐mir‐1299    dbDEMC
  hsa‐mir‐92b    dbDEMC             hsa‐mir‐455     PhenomiR
  hsa‐mir‐372    dbDEMC; PhenomiR   hsa‐mir‐144     dbDEMC; PhenomiR
  hsa‐mir‐151    dbDEMC; PhenomiR   hsa‐mir‐181c    dbDEMC; PhenomiR
  hsa‐mir‐32     dbDEMC; PhenomiR   hsa‐mir‐381     dbDEMC; PhenomiR
  hsa‐mir‐130b   dbDEMC; PhenomiR   hsa‐mir‐432     dbDEMC; PhenomiR
  hsa‐mir‐99b    dbDEMC; PhenomiR   hsa‐mir‐660     dbDEMC
  hsa‐mir‐28     dbDEMC; PhenomiR   hsa‐mir‐331     PhenomiR
  hsa‐mir‐449b   dbDEMC             hsa‐mir‐363     dbDEMC; PhenomiR
  hsa‐mir‐95     dbDEMC; PhenomiR   hsa‐mir‐382     dbDEMC
  hsa‐mir‐186    dbDEMC; PhenomiR   hsa‐mir‐154     dbDEMC; PhenomiR
  hsa‐mir‐196b   dbDEMC; PhenomiR   hsa‐mir‐663b    dbDEMC; PhenomiR
  hsa‐mir‐449a   dbDEMC; PhenomiR   hsa‐mir‐484     dbDEMC; PhenomiR
  hsa‐mir‐451    dbDEMC; PhenomiR   hsa‐mir‐520e    dbDEMC; PhenomiR
  hsa‐mir‐491    PhenomiR           hsa‐mir‐575     dbDEMC
  hsa‐mir‐99a    dbDEMC; PhenomiR   hsa‐mir‐663     dbDEMC; PhenomiR
  hsa‐mir‐424    dbDEMC; PhenomiR   hsa‐mir‐507     unconfirmed
  hsa‐mir‐212    dbDEMC; PhenomiR   hsa‐mir‐136     dbDEMC; PhenomiR
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Lung neoplasms is a malignant tumour that has the greatest threat to the health and life for people. It is also one of the fastest growing neoplasms in the incidence and mortality rate.[7](#jcmm13799-bib-0007){ref-type="ref"} Increasing evidence has suggested that miRNAs can not only be utilized to classify lung cancer, but also has the potential to be biomarkers for early diagnosis and clinical treatments. As shown in the table (Table [2](#jcmm13799-tbl-0002){ref-type="table"}), 49 of the top 50 the predicted candidates were verified to be associated with lung neoplasms. For example, previous research demonstrated that hsa‐mir‐106a and hsa‐mir‐106b (2nd in Table [2](#jcmm13799-tbl-0002){ref-type="table"}) can affect the growth and metastasis of lung neoplasms. The result further proved that our method could effectively predict miRNA‐disease associations in lung neoplasms.

###### 

The top 50 predicted miRNAs associated with lung neoplasms

  miRNA (1‐25)   Evidence           miRNA (26‐50)   Evidence
  -------------- ------------------ --------------- ------------------
  hsa‐mir‐16     dbDEMC; PhenomiR   hsa‐mir‐193b    dbDEMC; PhenomiR
  hsa‐mir‐106b   dbDEMC; PhenomiR   hsa‐mir‐302d    dbDEMC; PhenomiR
  hsa‐mir‐429    dbDEMC; PhenomiR   hsa‐mir‐99b     dbDEMC; PhenomiR
  hsa‐mir‐141    dbDEMC; PhenomiR   hsa‐mir‐28      dbDEMC; PhenomiR
  hsa‐mir‐15a    dbDEMC; PhenomiR   hsa‐mir‐153     dbDEMC; PhenomiR
  hsa‐mir‐20b    dbDEMC; PhenomiR   hsa‐mir‐488     dbDEMC; PhenomiR
  hsa‐mir‐195    dbDEMC; PhenomiR   hsa‐mir‐10a     dbDEMC
  hsa‐mir‐92b    dbDEMC; PhenomiR   hsa‐mir‐451     dbDEMC; PhenomiR
  hsa‐mir‐15b    dbDEMC; PhenomiR   hsa‐mir‐129     dbDEMC; PhenomiR
  hsa‐mir‐130a   dbDEMC; PhenomiR   hsa‐mir‐196b    dbDEMC; PhenomiR
  hsa‐mir‐302c   dbDEMC; PhenomiR   hsa‐mir‐452     dbDEMC; PhenomiR
  hsa‐mir‐302a   dbDEMC; PhenomiR   hsa‐mir‐299     PhenomiR
  hsa‐mir‐296    PhenomiR           hsa‐mir‐383     dbDEMC; PhenomiR
  hsa‐mir‐302b   dbDEMC; PhenomiR   hsa‐mir‐449a    dbDEMC; PhenomiR
  hsa‐mir‐372    dbDEMC; PhenomiR   hsa‐mir‐516a    unconfirmed
  hsa‐mir‐23b    dbDEMC; PhenomiR   hsa‐mir‐424     dbDEMC; PhenomiR
  hsa‐mir‐194    dbDEMC; PhenomiR   hsa‐mir‐139     dbDEMC; PhenomiR
  hsa‐mir‐373    dbDEMC; PhenomiR   hsa‐mir‐342     dbDEMC; PhenomiR
  hsa‐mir‐520b   dbDEMC             hsa‐mir‐449b    dbDEMC; PhenomiR
  hsa‐mir‐204    dbDEMC; PhenomiR   hsa‐mir‐99a     dbDEMC; PhenomiR
  hsa‐mir‐339    dbDEMC; PhenomiR   hsa‐mir‐491     dbDEMC
  hsa‐mir‐367    dbDEMC; PhenomiR   hsa‐mir‐181d    dbDEMC; PhenomiR
  hsa‐mir‐215    dbDEMC; PhenomiR   hsa‐mir‐149     dbDEMC; PhenomiR
  hsa‐mir‐130b   dbDEMC; PhenomiR   hsa‐mir‐340     dbDEMC; PhenomiR
  hsa‐mir‐151    PhenomiR           hsa‐mir‐301b    dbDEMC
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Prostate neoplasms is also one of the common diseases in men. It is estimated that one in six men in the United States will be diagnosed with prostate cancer in their lifetime, with the likelihood increasing with age.[54](#jcmm13799-bib-0054){ref-type="ref"} Studies have shown that miR‐182‐5p can be used as a marker for the diagnosis of prostate neoplasms and miR‐20 plays a vital role in the occurrence of prostate cancer.[55](#jcmm13799-bib-0055){ref-type="ref"} Therefore, identifying miRNAs related with prostate neoplasms is of great importance. As shown in Table [3](#jcmm13799-tbl-0003){ref-type="table"}, 48 candidate miRNAs were verified to be correctly related with prostate neoplasms. Only two miRNAs, hsa‐mir‐34c and hsa‐mir‐486, were not recorded in the two databases. As a matter of fact, studies have revealed that hsa‐mir‐34c together with hsa‐mir‐34a and hsa‐mir‐34b are the most frequently reported epigenetically dysregulated miRNAs.[56](#jcmm13799-bib-0056){ref-type="ref"} Our prediction was also in accordance with this result and provided new evidence for its association with prostate cancer. Besides, several studies have confirmed that hsa‐mir‐486 plays a important part in prostate cancer through negative regulation of multiple tumour suppressor pathways.[57](#jcmm13799-bib-0057){ref-type="ref"}

###### 

The top 50 predicted miRNAs associated with prostate neoplasms

  miRNA (1‐25)   Evidence           miRNA (26‐50)   Evidence
  -------------- ------------------ --------------- ------------------
  hsa‐mir‐21     dbDEMC; PhenomiR   hsa‐mir‐223     dbDEMC; PhenomiR
  hsa‐mir‐155    dbDEMC; PhenomiR   hsa‐mir‐29a     dbDEMC; PhenomiR
  hsa‐mir‐17     dbDEMC; PhenomiR   hsa‐mir‐203     dbDEMC; PhenomiR
  hsa‐mir‐146a   PhenomiR           hsa‐mir‐100     dbDEMC; PhenomiR
  hsa‐mir‐20a    dbDEMC; PhenomiR   hsa‐mir‐29b     dbDEMC; PhenomiR
  hsa‐mir‐34a    dbDEMC; PhenomiR   hsa‐mir‐31      dbDEMC; PhenomiR
  hsa‐mir‐126    dbDEMC; PhenomiR   hsa‐mir‐146b    dbDEMC; PhenomiR
  hsa‐mir‐92a    dbDEMC; PhenomiR   hsa‐let‐7d      dbDEMC; PhenomiR
  hsa‐let‐7a     dbDEMC; PhenomiR   hsa‐mir‐29c     dbDEMC; PhenomiR
  hsa‐mir‐200b   dbDEMC; PhenomiR   hsa‐mir‐205     dbDEMC; PhenomiR
  hsa‐mir‐200c   dbDEMC; PhenomiR   hsa‐mir‐214     dbDEMC; PhenomiR
  hsa‐mir‐143    dbDEMC; PhenomiR   hsa‐mir‐222     dbDEMC; PhenomiR
  hsa‐mir‐200a   dbDEMC; PhenomiR   hsa‐mir‐182     dbDEMC; PhenomiR
  hsa‐mir‐16     dbDEMC; PhenomiR   hsa‐mir‐133b    dbDEMC; PhenomiR
  hsa‐mir‐221    dbDEMC; PhenomiR   hsa‐mir‐375     dbDEMC; PhenomiR
  hsa‐mir‐1      dbDEMC; PhenomiR   hsa‐mir‐101     dbDEMC; PhenomiR
  hsa‐mir‐18a    dbDEMC; PhenomiR   hsa‐mir‐34b     PhenomiR
  hsa‐let‐7b     dbDEMC; PhenomiR   hsa‐mir‐210     dbDEMC; PhenomiR
  hsa‐mir‐199a   dbDEMC; PhenomiR   hsa‐mir‐218     dbDEMC; PhenomiR
  hsa‐mir‐15a    dbDEMC; PhenomiR   hsa‐mir‐9       PhenomiR
  hsa‐mir‐141    dbDEMC; PhenomiR   hsa‐mir‐142     PhenomiR
  hsa‐mir‐19a    dbDEMC; PhenomiR   hsa‐mir‐27a     dbDEMC; PhenomiR
  hsa‐mir‐19b    dbDEMC; PhenomiR   hsa‐mir‐133a    dbDEMC; PhenomiR
  hsa‐mir‐34c    unconfirmed        hsa‐let‐7e      dbDEMC; PhenomiR
  hsa‐let‐7c     dbDEMC; PhenomiR   hsa‐mir‐486     unconfirmed
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The second type of case study mainly aims to prove the ability of our method in predicting new associations for diseases without any known related miRNAs. To this end, we selected another disease pancreatic neoplasms for the following analysis. Pancreatic neoplasms is a malignant tumour of the digestive tract that is highly malignant and difficult to diagnose and treat in the world.[58](#jcmm13799-bib-0058){ref-type="ref"} Many studies have found that the differential expression of miRNAs in pancreatic neoplasms is closely related to the occurrence of tumours. Here, we first removed all known entries associated with pancreatic neoplasms in HMDD v2.0, and thus, all 495 miRNAs were considered as candidate miRNAs. Then, we used our model to prioritize these candidate miRNAs and obtained their corresponding rankings associated with pancreatic neoplasms. We found that all the top 50 predicted miRNAs were confirmed either by dbDEMC, PhenomiR or HMDD v2.0 (Table [4](#jcmm13799-tbl-0004){ref-type="table"}). The result proved that our method could be applied to predict potential associations for disease without any known related miRNAs.

###### 

The top 50 predicted miRNAs associated with pancreatic neoplasms

  miRNA (1‐25)   Evidence                miRNA (26‐50)   Evidence
  -------------- ----------------------- --------------- -----------------------
  hsa‐mir‐21     dbDEMC; PhenomiR;HMDD   hsa‐mir‐31      dbDEMC; PhenomiR;HMDD
  hsa‐mir‐155    dbDEMC; PhenomiR;HMDD   hsa‐mir‐19b     dbDEMC; PhenomiR
  hsa‐mir‐146a   dbDEMC; PhenomiR;HMDD   hsa‐mir‐19a     dbDEMC; PhenomiR
  hsa‐mir‐125b   dbDEMC; PhenomiR;HMDD   hsa‐mir‐141     dbDEMC; PhenomiR
  hsa‐mir‐145    dbDEMC; PhenomiR;HMDD   hsa‐mir‐195     dbDEMC; PhenomiR
  hsa‐mir‐17     dbDEMC; PhenomiR;HMDD   hsa‐mir‐199a    dbDEMC; PhenomiR;HMDD
  hsa‐mir‐34a    dbDEMC; PhenomiR;HMDD   hsa‐mir‐29c     dbDEMC; PhenomiR
  hsa‐mir‐221    dbDEMC; PhenomiR;HMDD   hsa‐mir‐9       dbDEMC; PhenomiR
  hsa‐mir‐16     dbDEMC; PhenomiR;HMDD   hsa‐let‐7c      dbDEMC; PhenomiR;HMDD
  hsa‐mir‐126    dbDEMC; PhenomiR;HMDD   hsa‐mir‐210     dbDEMC; PhenomiR;HMDD
  hsa‐mir‐20a    dbDEMC; PhenomiR;HMDD   hsa‐mir‐375     dbDEMC; PhenomiR;HMDD
  hsa‐mir‐29a    dbDEMC; PhenomiR        hsa‐mir‐181a    dbDEMC; PhenomiR
  hsa‐let‐7a     dbDEMC; PhenomiR;HMDD   hsa‐mir‐133b    dbDEMC; PhenomiR;HMDD
  hsa‐mir‐200b   dbDEMC; PhenomiR;HMDD   hsa‐mir‐26a     dbDEMC; PhenomiR;HMDD
  hsa‐mir‐29b    dbDEMC; PhenomiR;HMDD   hsa‐mir‐122     dbDEMC; PhenomiR;HMDD
  hsa‐mir‐92a    dbDEMC; PhenomiR;HMDD   hsa‐mir‐133a    dbDEMC; PhenomiR
  hsa‐mir‐222    dbDEMC; PhenomiR;HMDD   hsa‐mir‐34c     HMDD
  hsa‐mir‐200c   dbDEMC; PhenomiR;HMDD   hsa‐let‐7d      dbDEMC; PhenomiR;HMDD
  hsa‐mir‐1      dbDEMC; PhenomiR        hsa‐let‐7e      dbDEMC; PhenomiR;HMDD
  hsa‐mir‐15a    dbDEMC; PhenomiR;HMDD   hsa‐mir‐182     dbDEMC; PhenomiR;HMDD
  hsa‐mir‐200a   dbDEMC; PhenomiR;HMDD   hsa‐mir‐203     dbDEMC; PhenomiR;HMDD
  hsa‐mir‐18a    dbDEMC; PhenomiR;HMDD   hsa‐mir‐142     HMDD
  hsa‐let‐7b     dbDEMC; PhenomiR;HMDD   hsa‐let‐7i      dbDEMC; PhenomiR;HMDD
  hsa‐mir‐143    dbDEMC; PhenomiR;HMDD   hsa‐mir‐30b     dbDEMC; PhenomiR
  hsa‐mir‐223    dbDEMC; PhenomiR;HMDD   hsa‐let‐7f      dbDEMC; PhenomiR;HMDD
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Finally, we conducted the last type of case study by taking the associations from older version of HMDD as input and test whether SNMDA could uncover those newly added associations in the latest version of HMDD. The older version of HMDD contained 1395 associations between 271 miRNAs and 137 diseases.[30](#jcmm13799-bib-0030){ref-type="ref"} Colorectal neoplasms were selected as the investigated disease. As a result, 49 of the top 50 predicted miRNAs have been confirmed to be related with colorectal neoplasms by HMDD 2.0, PhenomiR and dbDEMC (Table [5](#jcmm13799-tbl-0005){ref-type="table"}). The only unconfirmed miRNA was hsa‐mir‐205. However, studies have indicated that hsa‐mir‐205 is also associated with colorectal neoplasms.[59](#jcmm13799-bib-0059){ref-type="ref"} Taken together, all case studies have shown that SNMDA can effectively and reliably uncover the potential associations between miRNAs and diseases.

###### 

The top 50 predicted miRNAs associated with colorectal neoplasms

  miRNA (1‐25)   Evidence                 miRNA (26‐50)   Evidence
  -------------- ------------------------ --------------- ------------------------
  hsa‐mir‐221    dbDEMC; PhenomiR; HMDD   hsa‐mir‐126     dbDEMC; PhenomiR; HMDD
  hsa‐mir‐155    dbDEMC; PhenomiR; HMDD   hsa‐mir‐24      dbDEMC; PhenomiR
  hsa‐let‐7a     dbDEMC; PhenomiR; HMDD   hsa‐mir‐199a    PhenomiR; HMDD
  hsa‐mir‐19a    dbDEMC; PhenomiR; HMDD   hsa‐mir‐127     PhenomiR; HMDD
  hsa‐mir‐222    dbDEMC; PhenomiR; HMDD   hsa‐mir‐106b    dbDEMC; PhenomiR
  hsa‐let‐7b     dbDEMC; PhenomiR; HMDD   hsa‐mir‐30c     dbDEMC; PhenomiR
  hsa‐mir‐19b    dbDEMC; PhenomiR; HMDD   hsa‐mir‐191     dbDEMC; PhenomiR
  hsa‐let‐7e     dbDEMC; PhenomiR; HMDD   hsa‐mir‐15a     dbDEMC; PhenomiR
  hsa‐let‐7d     dbDEMC; PhenomiR         hsa‐mir‐214     dbDEMC; PhenomiR
  hsa‐mir‐146a   dbDEMC; PhenomiR; HMDD   hsa‐mir‐9       dbDEMC; PhenomiR; HMDD
  hsa‐let‐7f     dbDEMC; PhenomiR         hsa‐mir‐146b    PhenomiR; HMDD
  hsa‐let‐7c     dbDEMC; PhenomiR; HMDD   hsa‐mir‐101     dbDEMC; PhenomiR
  hsa‐mir‐223    dbDEMC; PhenomiR         hsa‐mir‐125a    dbDEMC; PhenomiR
  hsa‐mir‐200b   dbDEMC; PhenomiR; HMDD   hsa‐mir‐25      dbDEMC; PhenomiR; HMDD
  hsa‐let‐7i     dbDEMC; PhenomiR         hsa‐mir‐29a     dbDEMC; PhenomiR; HMDD
  hsa‐mir‐125b   dbDEMC; PhenomiR; HMDD   hsa‐mir‐20b     dbDEMC; PhenomiR
  hsa‐mir‐34a    dbDEMC; PhenomiR; HMDD   hsa‐mir‐200a    dbDEMC; PhenomiR; HMDD
  hsa‐let‐7 g    dbDEMC; PhenomiR         hsa‐mir‐150     dbDEMC; PhenomiR; HMDD
  hsa‐mir‐92a    dbDEMC; PhenomiR; HMDD   hsa‐mir‐205     unconfuirmed
  hsa‐mir‐29b    dbDEMC; PhenomiR         hsa‐mir‐34c     PhenomiR; HMDD
  hsa‐mir‐16     dbDEMC; PhenomiR; HMDD   hsa‐mir‐133a    dbDEMC; PhenomiR; HMDD
  hsa‐mir‐132    dbDEMC; PhenomiR         hsa‐mir‐107     dbDEMC; PhenomiR; HMDD
  hsa‐mir‐141    dbDEMC; PhenomiR; HMDD   hsa‐mir‐32      dbDEMC; PhenomiR
  hsa‐mir‐1      dbDEMC; PhenomiR; HMDD   hsa‐mir‐93      dbDEMC; PhenomiR; HMDD
  hsa‐mir‐106a   dbDEMC; PhenomiR; HMDD   hsa‐mir‐429     dbDEMC; PhenomiR
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4. DISCUSSION {#jcmm13799-sec-0017}
=============

As it is unrealistic to make a large scale of prediction based on traditional experimental methods, identifying the associations buried in miRNAs and diseases based on computational models is still a hot topic, and it remains a challenging task to discover such associations accurately and efficiently. Therefore, we proposed a novel method based on sparse neighbourhood to predict miRNA‐disease associations. First, sparse reconstruction was used to obtain a reconstructed miRNA similarity and a disease similarity. Second, similarity information was integrated to construct a similarity network for miRNA and disease, respectively. Finally, label propagation was applied on the miRNA similarity network as well as disease similarity network to obtain the relevance scores for each miRNA‐disease association. Besides, we applied global LOOCV, local LOOCV and 5‐fold cross‐validation to test the prediction performance and SNMDA achieved remarkable results in all the three cross‐validation frameworks. In addition, we compared SNMDA with four state‐of‐the‐art methods and the results demonstrated the superior performance of SNMDA. The prediction ability of our method was further verified by three types of case studies on five common diseases.

The success of our model could be mainly attributed to two reasons. First, the reconstructed miRNA similarities and disease similarities based on the sparse neighbourhood have greatly compensated for the incompleteness of current data sets due to the inherent sparsity of the constructed miRNA‐disease network. Second, the label propagation process on both miRNA and disease networks ensured that the known labels were reliably propagated according to the reconstructed similarities. Nonetheless, the performance of SNMDA was sensitive to the quality of the miRNA similarity network and disease similarity network. More data sources should be integrated into our model to further improve the prediction accuracy of our model. Moreover, we simply combined the reconstructed similarity matrices with the precalculated similarity matrices by adding them together with equal weights, which might be a suboptimal result for the overall similarity. In conclusion, we believe that SNMDA could serve as a powerful tool for the prediction of miRNA‐disease associations.
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**ALGORITHM 1:** SNMDA algorithm {#jcmm13799-sec-0020}
================================

**Input:** Matrices *Y* ^*n*\ ×\ *m*^, MFS^*n*\ ×\ *n*^, DSS^*m*\ ×\ *m*^, parameter *α*,*β***Output:** Predicted associations matrix *F*.1: For *i ←* 1 to *n* do2: Select the sparse neighborhood for miRNA *i* by Equation [(5)](#jcmm13799-disp-0005){ref-type="disp-formula"}.3: End for4: Obtain a reconstructed miRNA similarity matrix by Equation [(6)](#jcmm13799-disp-0006){ref-type="disp-formula"}.5: For *j ←* 1 to *m* do6: Select the sparse neighborhood for disease *j* by Equation [(5)](#jcmm13799-disp-0005){ref-type="disp-formula"}.7: End for8: Obtain a reconstructed disease similarity matrix by Equation [(6)](#jcmm13799-disp-0006){ref-type="disp-formula"}.9: Integrate similarity information by Equations [(7)](#jcmm13799-disp-0007){ref-type="disp-formula"} and [(8)](#jcmm13799-disp-0008){ref-type="disp-formula"}.10: Repeat11: $F_{M}\left( {t + 1} \right) = \alpha{} \ast MS{} \ast F_{M}\left( t \right) + \left( {1 - \alpha} \right){} \ast Y$12: Until convergence13: Repeat14: $F_{D}\left( {t + 1} \right) = \alpha{} \ast DS{} \ast F_{D}\left( t \right) + \left( {1 - \alpha} \right){} \ast Y^{\prime}$15*:* Until convergence16: $F = \beta F_{M} + \left( {1 - \beta} \right){F_{D}}^{\prime}$17: **Return** *F*
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